SEC Form 4 · accession 0001171843-18-001149
Xenon Pharmaceuticals Inc. · XENE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles J. Cohen
Officer — VP, Biology
Period of report
Feb 12, 2018
Accepted (ET)
Feb 14, 2018 · 5:55 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001582313
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | Feb 12, 2018 | M | 26,748 | $3.71 | A | 26,748 | D | |
| Common SharesF2 | Feb 12, 2018 | F | 22,669 | $3.50 | D | 4,079 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F3 | $3.71 | Feb 12, 2018 | M | 26,748 | D | — | Mar 16, 2018 | Common Shares | 26,748 | 0 | D |
Explanation of responses
- F1The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.
- F2Represents the closing price of the Company's common shares on February 09, 2018, which was converted to $4.41 Canadian for purposes of net settlement calculations.
- F3The shares subject to the option fully vested on January 31, 2012. The date the option became fully vested was incorrectly reflected on the Reporting Person's Form 3.